TY - JOUR
T1 - Efficacy of atorvastatin therapy in ischaemic heart disease - Effects on oxidized low-density lipoprotein and adiponectin
AU - Miyagishima, K.
AU - Hiramitsu, Shinya
AU - Kato, S.
AU - Kato, Y.
AU - Kitagawa, F.
AU - Teradaira, R.
AU - Shinohara, R.
AU - Mori, K.
AU - Kimura, H.
AU - Ueda, T.
AU - Ohtsuki, M.
AU - Morimoto, S.
AU - Hishida, H.
PY - 2007
Y1 - 2007
N2 - The lipid-lowering and anti-atherosclerotic effects of atorvastatin (10 mg/day) were investigated by measuring changes in the levels of oxidized low-density lipoprotein (LDL), serum lipids (total cholesterol [TC], LDL-cholesterol [LDL-C] and triglycerides [TG]), and in the protein adiponectin. This was undertaken in 22 patients with ischaemic heart disease and serum LDL-C levels > 100 mg/dl. After 3 months of therapy, atorvastatin significantly decreased serum lipids, oxidized LDL was reduced from 457.0 ± 148.6 to 286.9 ± 88.5 nmol/l, and adiponectin increased from 9.7 ± 7.4 to 13.9 ± 9.98 μg/ ml. No significant correlation was observed between adiponectin and LDL-C, TG and high-density lipoprotein cholesterol. Atorvastatin therapy was not associated with side-effects, such as myalgia and gastrointestinal disorders, and did not give abnormal laboratory test results. It is concluded that atorvastatin decreases serum lipid and oxidized LDL levels, and increases adiponectin levels in patients with ischaemic heart disease.
AB - The lipid-lowering and anti-atherosclerotic effects of atorvastatin (10 mg/day) were investigated by measuring changes in the levels of oxidized low-density lipoprotein (LDL), serum lipids (total cholesterol [TC], LDL-cholesterol [LDL-C] and triglycerides [TG]), and in the protein adiponectin. This was undertaken in 22 patients with ischaemic heart disease and serum LDL-C levels > 100 mg/dl. After 3 months of therapy, atorvastatin significantly decreased serum lipids, oxidized LDL was reduced from 457.0 ± 148.6 to 286.9 ± 88.5 nmol/l, and adiponectin increased from 9.7 ± 7.4 to 13.9 ± 9.98 μg/ ml. No significant correlation was observed between adiponectin and LDL-C, TG and high-density lipoprotein cholesterol. Atorvastatin therapy was not associated with side-effects, such as myalgia and gastrointestinal disorders, and did not give abnormal laboratory test results. It is concluded that atorvastatin decreases serum lipid and oxidized LDL levels, and increases adiponectin levels in patients with ischaemic heart disease.
UR - http://www.scopus.com/inward/record.url?scp=34547887274&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34547887274&partnerID=8YFLogxK
U2 - 10.1177/147323000703500413
DO - 10.1177/147323000703500413
M3 - Article
C2 - 17697531
AN - SCOPUS:34547887274
SN - 0300-0605
VL - 35
SP - 534
EP - 539
JO - Journal of International Medical Research
JF - Journal of International Medical Research
IS - 4
ER -